Processa Pharmaceuticals, Inc. Proceeds from Unsecured Notes Payable
Processa Pharmaceuticals, Inc. (PCSA) reported Proceeds from Unsecured Notes Payable of -$4.74 thousand for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromUnsecuredNotesPayable · last filed 2019-08-14
- Processa Pharmaceuticals, Inc. proceeds from unsecured notes payable for the quarter ending 2018-09-30 was -$9.48K.
- Processa Pharmaceuticals, Inc. proceeds from unsecured notes payable for the quarter ending 2014-12-31 was $95.00K.
- Processa Pharmaceuticals, Inc. proceeds from unsecured notes payable for the quarter ending 2014-09-30 was $579.00K.
- Processa Pharmaceuticals, Inc. proceeds from unsecured notes payable for the quarter ending 2014-06-30 was $570.00K.
- Processa Pharmaceuticals, Inc. proceeds from unsecured notes payable for fiscal 2017 was $2.58M.
- Processa Pharmaceuticals, Inc. proceeds from unsecured notes payable for fiscal 2014 was $2.24M, a 2393.34% increase from fiscal 2013.
- Processa Pharmaceuticals, Inc. proceeds from unsecured notes payable for fiscal 2013 was $90.00K.
| Period end | Proceeds from Unsecured Notes Payable 3 month | Proceeds from Unsecured Notes Payable 6 month | Proceeds from Unsecured Notes Payable 9 month | Proceeds from Unsecured Notes Payable 12 month | Proceeds from Unsecured Notes Payable 33 month | Proceeds from Unsecured Notes Payable 36 month |
|---|---|---|---|---|---|---|
| 2018-09-30 | -$9.48K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$4.74K 10-Q · filed 2018-11-14 | ||||
| 2018-06-30 | $4.74K 10-Q · filed 2019-08-14 | |||||
| 2017-12-31 | $2.58M 10-K · filed 2018-04-16 | |||||
| 2014-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-06-19 | $674.00K derived: sum of 2 quarters · filed 2017-06-19 | $1.24M derived: sum of 3 quarters · filed 2017-06-19 | $2.24M 10-K · filed 2017-06-19 | ||
| 2014-09-30 | $579.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-12-01 | $1.15M derived: sum of 2 quarters · filed 2015-12-01 | $2.15M 10-Q · filed 2015-12-01 | |||
| 2014-06-30 | $570.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-19 | $1.57M 10-Q · filed 2015-08-19 | ||||
| 2014-03-31 | $1.00M 10-Q · filed 2015-05-15 | $1.09M 10-Q · filed 2014-05-14 | ||||
| 2013-12-31 | $90.00K 10-K · filed 2015-04-14 | $90.00K 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |